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a b s t r a c t
Recently, cell culture systems producing hepatitis C virus particles (HCVcc) were developed. Establish-
ment of serum-free culture conditions is expected to facilitate development of a whole-virus inactivated
HCV vaccine. We describe generation of genotype 1–6 serum-free HCVcc (sf-HCVcc) from Huh7.5
hepatoma cells cultured in adenovirus expression medium. Compared to HCVcc, sf-HCVcc showed
0.6–2.1 log10 higher infectivity titers (4.7–6.2 log10 Focus Forming Units/mL), possibly due to increased
release and speciﬁc infectivity of sf-HCVcc. In contrast to HCVcc, sf-HCVcc had a homogeneous single-
peak density proﬁle. Entry of sf-HCVcc depended on HCV co-receptors CD81, LDLr, and SR-BI, and
clathrin-mediated endocytosis. HCVcc and sf-HCVcc were neutralized similarly by chronic-phase patient
sera and by human monoclonal antibodies targeting conformational epitopes. Thus, we developed
serum-free culture systems producing high-titer single-density sf-HCVcc, showing similar biological
properties as HCVcc. This methodology has the potential to advance HCV vaccine development and to
facilitate biophysical studies of HCV.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Hepatitis C virus (HCV) is a major public healthcare burden
with 3–4 million new infections occurring each year and more
than 150 million individuals estimated to be chronically infected
worldwide (Fauvelle et al., 2013). Many of these individuals
develop serious chronic liver diseases such as cirrhosis and
hepatocellular carcinoma, making HCV the most frequent cause
of liver transplantation (Alter and Seeff, 2000).
HCV is an enveloped, positive-stranded RNA virus of the genus
Hepacivirus within the Flaviviridae family. Due to a high degree of
genetic heterogeneity, HCV has been classiﬁed into 6 epidemiolo-
gically important genotypes and numerous subtypes, differing in
approximately 30% and 20% of their nucleotide and amino acid
sequence, respectively (Simmonds et al., 2005; Gottwein and
Bukh, 2008). Genotypes show important clinical and biological
differences (Amoroso et al., 1998; Cross et al., 2010; Prentoe et al.,
2011; Scheel et al., 2012; Sarrazin et al., 2012; Scheel and Rice,
2013). Serotypes have not been deﬁned; however, different geno-
types and subtypes show differential sensitivity to neutralizing
antibodies found in sera of chronically infected patients and to
monoclonal neutralizing antibodies with therapeutic potential
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(Meunier et al., 2005; Jensen et al., 2008; Gottwein et al., 2009;
Prentoe et al., 2011; Giang et al., 2012).
The 9.6 kb HCV genome consists of 5ʹ and 3ʹ untranslated
regions and a single open reading frame encoding structural
proteins (Core, E1 and E2), the viroporin p7, and nonstructural
proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B) (Gottwein and
Bukh, 2008). The HCV virion is believed to consist of a nucleo-
capsid of HCV Core proteins containing the genomic RNA, covered
by a lipid envelope with the HCV envelope glycoproteins E1 and
E2. The HCV life cycle is tightly linked to the hepatic lipid
metabolism. During assembly and release, the HCV virion is
believed to associate with very-low-density-lipoprotein (VLDL)
or VLDL-like structures, creating lipo-viro-particles (LVP)
(Popescu and Dubuisson, 2010; Felmlee et al., 2013). Thus, HCV
apparently circulates in infected patients associated to different
classes of lipoproteins (Felmlee et al., 2013), resulting in a hetero-
geneous density proﬁle apparent following buoyant density gra-
dient ultracentrifugation (Nielsen et al., 2006; Felmlee et al., 2013).
Components of the VLDL assembly and secretion pathway, such as
apolipoprotein E (ApoE), might be important for the association
between HCV and lipoproteins (Chang et al., 2007).
HCV entry is mediated by several co-receptors, including CD81,
the low-density-lipoprotein receptor (LDLr) and the scavenger
receptor class B type I (SR-BI) (Ploss and Evans, 2012). While
HCV is believed to interact directly with CD81 through E2 (Pileri
et al., 1998; McKeating et al., 2004), interactions with other
receptors, such as LDLr and SR-BI, might occur through lipoprotein
components present on the LVP, such as ApoE (Owen et al., 2009;
Thi et al., 2012), although direct interactions between E2 and SR-BI
have also been reported (Scarselli et al., 2002; Thi et al., 2012).
Eventually, HCV is internalized through clathrin-mediated endo-
cytosis (Blanchard et al., 2006; Meertens et al., 2006).
There is no vaccine available for HCV. Current standard-of-care,
based on pegylated interferon-α2 and ribavirin, has limited efﬁcacy
and is associated with severe side effects and contraindications
(Sarrazin et al., 2012). Even though promising new compounds for
treatment of HCV are being developed and licenced (Sarrazin et al.,
2012; Scheel and Rice, 2013), only a minority of HCV-infected
individuals is expected to be diagnosed and treated, mainly due to
the asymptomatic nature of infection, economic constraints and
contraindications (Fauvelle et al., 2013). Thus, an HCV vaccine is
needed to control HCV globally. Most successful antiviral vaccines
employ inactivated or attenuated whole viral particles as vaccine
antigen and depend on the induction of neutralizing antibodies
(Plotkin, 2008; Plotkin and Plotkin, 2011). Due to a lack of HCV
particle-producing cell culture systems, this approach was not
feasible for HCV (Steinmann and Pietschmann, 2013; Lohmann
and Bartenschlager, 2014).
Only in 2005, the ﬁrst HCV cell culture system supporting the full
viral life cycle was developed, based on the genotype 2a isolate JFH1
and the human hepatoma cell line Huh7 and derived cell lines
(Wakita et al., 2005; Lindenbach et al., 2005; Zhong et al., 2005).
Subsequently, culture systems producing HCV particles (HCVcc) of
the major genotypes were developed using JFH1-based recombinants
expressing genotype speciﬁc Core, E1, E2, p7 and NS2 (Pietschmann
et al., 2006; Gottwein et al., 2007; Yi et al., 2007; Scheel et al., 2008;
Jensen et al., 2008; Gottwein et al., 2009). Such particles could serve
as antigens in a whole-virus inactivated HCV vaccine primarily
aiming at induction of neutralizing antibodies against structural
proteins of the major HCV genotypes.
However, HCVcc yields from the developed cell culture systems
are relatively low compared to quantities envisioned to be required
for vaccine production. Further, as patient derived HCV particles
(Nielsen et al., 2006), HCVcc showed a heterogeneous density proﬁle
(Lindenbach et al., 2005; Lindenbach et al., 2006; Gastaminza et al.,
2006; Prentoe et al., 2011), making density-based puriﬁcation and
concentration procedures difﬁcult. Also, cell cultures are typically
treated with animal-derived trypsin, and growth medium used for
production of HCVcc is typically supplemented with fetal bovine
serum (FBS). Vaccine development, as well as other research applica-
tions, such as biophysical studies of HCV particle composition, require
generation of puriﬁed and concentrated HCVcc stocks. This is
expected to be facilitated by reducing concentrations of non-HCV
proteins such as FBS derived proteins in HCVcc producing cell
cultures. Further, use of FBS and animal-derived trypsin increases
the risk of contamination with adventitious microbial agents, of
relevance for HCV vaccine development (WHO, 1998; Houghton
et al., 2013). Thus, development of methods for production of HCVcc
under serum-free conditions is a research focus. At the onset of this
study it had been demonstrated that Huh7 cells could be cultured in
serum-free medium (RPMI 1640 supplemented with Na2SeO3) with-
out previous adaptation for an extended period of time, and that
serum-free cell cultures (DMEM supplemented with Na2SeO3 and
lipid rich albumin) allowed replication of HCV (Nakabayashi et al.,
1982; Abe et al., 2007).
In this study, we aimed at developing and characterizing
serum-free genotype 1–6 HCVcc particles (sf-HCVcc). From
infected Huh7.5 cell cultures maintained in adenovirus expression
medium (AEM) without using trypsin, we were able to harvest
genotype 1–6 sf-HCVcc containing culture supernatants. The sf-
HCVcc particles were characterized by increased infectivity titers
and an altered density proﬁle with a single infectivity peak,
expected to facilitate density-based puriﬁcation procedures. How-
ever, sf-HCVcc showed similar biological properties as HCVcc
regarding routes of viral entry and susceptibility to neutralizing
antibodies. Establishment of a robust methodology for generation
of high-titer single-density serum-free HCVcc is expected to aid
HCV vaccine development.
Results
Huh7.5 cells cultured in serum-free medium yield higher HCV
infectivity titers than conventional cultures
To produce sf-HCVcc, HCV recombinants were cultured in
Huh7.5 cells maintained in AEM, a commercially available cell
culture medium without animal or human serum as described in
“Materials and methods” section. Because AEM cultured Huh7.5
cells did not tolerate detachment, AEM was replaced every 2–3
days without splitting the cells. Thus, animal-derived trypsin was
not used during the virus production phase. Cultures handled in
this manner became over-conﬂuent but could be maintained for at
least 29 days (data not shown).
We tested if AEM cultured cells supported production of sf-
HCVcc. Huh7.5 cells cultured in DMEMþ10% FBS were initially
infected with JFH1-based Core-NS2 recombinants H77(1a), J4(1b),
S52(3a) and ED43(4a) (Gottwein et al., 2009) (Fig. 1). When viral
infection had spread to 80% of culture cells, as determined by
immunostaining of HCV NS5A antigen, one replicate culture was
maintained in AEM and another in DMEMþ10% FBS. Similar to
previous observations (Gottwein et al., 2009), HCVcc peak super-
natant infectivity titers were 3.4–4.2 log10 Focus Forming Units
(FFU)/ml, followed by a drop in infectivity titers, when virus induced
cell death was observed (Fig. 1) (Gottwein et al., 2007). For sf-HCVcc,
peak infectivity titers were higher than for HCVcc, reaching 4.6–
5.0 log10 FFU/ml (Fig. 1). Also, relatively high infectivity titers were
maintained for a longer period for sf-HCVcc than for HCVcc.
We next aimed at producing sf-HCVcc virus stocks of prototype
strains of the six major HCV genotypes and epidemiologically
important subtype 1b for further characterization. We infected
Huh7.5 cells cultured in DMEMþ10% FBS with Core-NS2
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recombinants indicated in Fig. 2. DMEMþ10% FBS was replaced by
AEM, when 40–80% of culture cells were infected (Fig. 2). From
these cultures, high-titer sf-HCVcc virus stocks were harvested at
four consecutive time points, before cultures were closed. Peak
infectivity titers between 4.7 and 6.2 log10 FFU/ml were observed
for sf-HCVcc, with sf-J4(1b) and sf-ED43(4a) showing the lowest
and sf-SA13(5a) showing the highest titers (Fig. 2 and Table 1).
Thus, sf-HCVcc stocks showed 0.6–2.1 log10 FFU/mL increased
infectivity titers compared to previously described HCVcc refer-
ence stocks (Table 1) (Gottwein et al., 2009). HCV RNA and Core
titers for sf-HCVcc and HCVcc reference stocks were similar
(Table 1). Thus, genotype 1–6 sf-HCVcc showed increased speciﬁc
infectivities compared to HCVcc reference stocks (Table 1). This
increase in speciﬁc infectivity was most pronounced for recombi-
nants with comparatively low infectivity titers. Thus, based on
RNA titers, speciﬁc infectivity was 20-fold increased for sf-J4(1b)
and 40-fold increased for sf-ED43(4a) compared to their HCVcc
counterparts (Table 1). This resulted in differences in speciﬁc
infectivity between sf-HCVcc of different genotypes being smaller
than those between HCVcc of different genotypes. For sf-HCVcc,
based on RNA titers, speciﬁc infectivities were between 1/40 FFU/IU
and 1/631 FFU/IU, while HCVcc showed speciﬁc infectivities between
1/398 FFU/IU and 1/12,589 FFU/IU (Table 1).
Higher infectivity titers of sf-HCVcc might be due to increased
viral release and speciﬁc infectivity
We next aimed at determining if the observed differences in
infectivity titers were due to the fact that DMEMþ10% FBS
cultures were split at regular intervals, while AEM cultures were
kept over-conﬂuent. Huh7.5 cell cultures were infected with
SA13(5a) and (i) maintained in DMEMþ10% FBS and split every
2–3 days, (ii) maintained in DMEMþ10% FBS without splitting, or
(iii) maintained in AEM without splitting (Fig. 3A). The
DMEMþ10% FBS culture yielded a peak infectivity titer of
5.6 log10 FFU/ml, while the AEM culture yielded a peak infectivity
titer of 6.1 log10 FFU/ml (Fig. 3A). However, the DMEMþ10% FBS
culture maintained without splitting reached only 4.6 log10 FFU/
mL (Fig. 3A). This suggested that the high infectivity titers
observed for the AEM cultures were not due to reduced stress
related to avoiding cell culture splitting.
We subsequently investigated cell viability and proliferation
of cells cultured in AEM versus DMEMþ10% FBS. After 48 h of
culture in AEM, when increased infectivity titers were observed,
cell viability and proliferation of AEM cultures was similar to that
of DMEMþ10% FBS cultures (Fig. 3B). Thus, changes in cell
viability or proliferation did not explain the increased infectivity
titers observed.
We further investigated, whether sf-HCVcc were more stable
than HCVcc, which might contribute to the observed increase in
infectivity titers. Up to 5 freeze/thaw cycles did not result in major
decrease in infectivity or differences in infectivity for SA13(5a), sf-
SA13(5a) or sf-SA13(5a) supplemented with 10% FBS (Fig. 3C).
Incubation for 48 h at 4 1C resulted in a minor decrease in
infectivity of sf-SA13(5a) compared to SA13(5a) and sf-SA13(5a)
supplemented with 10% FBS (Fig. 3D). Incubation for 4–48 h at
room temperature or 37 1C resulted in a gradual decrease in
infectivity; this decrease was more pronounced for sf-SA13(5a)
Fig. 1. Serum-free Huh7.5 cell cultures produced high-titer sf-HCVcc. Huh7.5 cells were infected with the indicated JFH1-based Core-NS2 recombinants in DMEMþ10% FBS for
18 h. Cells were split into two replicate DMEMþ10% FBS cultures. When 80% of culture cells were infected, as determined by HCV NS5A immunostaining, one replicate culture
was maintained in DMEMþ10% FBS (black bars), while the other replicate culture was maintained in AEM (gray bars). At the indicated day post infection, supernatants were
collected and DMEMþ10% FBS cultures were split, while fresh medium was added to AEM cultures as described in “Materials and methods” section. Supernatant HCVcc
infectivity titers are shown as means of 3 replicates with standard error of the mean (SEM). The lower limit of detection in the experiments shown was up to 2.7 log10 FFU/ml,
indicated by y-axis break. nAt this time point, the experiment consisted only of replicate cultures maintained in DMEMþ10% FBS; only one culture was titrated.
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than for SA13(5a), and partially rescued by addition of 10% FBS to
sf-SA13(5a) (Fig. 3D). Thus, FBS might result in stabilization of
HCVcc. However, apparently, increased infectivity titers were not
caused by increased stability of sf-HCVcc.
In order to investigate whether certain steps of the viral life
cycle were affected by serum-free culture conditions, we carried
out single-cycle virus production assays using CD81-deﬁcient S29
cells, which are derived from Huh7.5 cells (Russell et al., 2008).
Following transfection with SA13(5a) HCV RNA, AEM cultures
showed a 1 log decrease in intracellular HCV Core and infectivity
titers compared to DMEMþ10% FBS cultures, indicating a decrease
in viral replication/translation (Fig. 4A and B). In contrast, AEM
and DMEMþ10% FBS cultures showed similar extracellular Core
titers, but AEM cultures had a 1 log increase in extracellular
infectivity titers compared to DMEMþ10% FBS cultures. These
ﬁndings suggest that AEM culture resulted in increased viral
release and that sf-HCVcc had increased speciﬁc infectivity com-
pared to HCVcc. Furthermore, for HCVcc, the peak extracellular
infectivity titer was observed 48 h post transfection followed by a
decrease at 72 h post transfection, while for sf-HCVcc high titers
were observed at both time points (Fig. 4B). This is in agreement
with the prolonged peak of infection observed in Huh7.5 cells
(Figs. 1–3).
Infectious sf-HCVcc particles displayed a homogeneous density proﬁle
To investigate their biophysical properties we subjected
sf-HCVcc (Fig. 2) to equilibrium buoyant density ultracentrifuga-
tion on iodixanol gradients. As described previously for genotypes
2a, 3a, 5a and 6a HCVcc (Lindenbach et al., 2005; Lindenbach et al.,
Fig. 2. Generation of genotype 1–6 sf-HCVcc virus stocks. Huh7.5 cells were infected with the indicated viruses in DMEMþ10% FBS at an MOI of 0.003 for 6 h. On days 6–15
post infection, depending on the growth kinetics of the respective virus, when 40–80% of culture cells were infected, as determined by HCV NS5A immunostaining,
DMEMþ10% FBS was replaced by AEM. At the indicated day post infection, supernatant was collected and fresh AEM was added to the cells. Supernatant HCVcc infectivity
titers are shown as means of 3 replicates with standard error of the mean (SEM). Black bars represent DMEMþ10% FBS supernatant HCVcc infectivity titers; gray bars
represent AEM supernatant sf-HCVcc infectivity titers. The lower limit of detection in the experiments shown was up to 2.3 log10 FFU/ml, indicated by y-axis break.
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2006; Gastaminza et al., 2006; Prentoe et al., 2011), we observed
that infectious genotype 1–6 HCVcc particles constituted hetero-
geneous virus populations with buoyant densities between 1.01–
1.10 g/mL (Fig. 5). Interestingly, for genotype 1–6 sf-HCVcc har-
vested after 48 h of cell culture with AEM, we detected up
to 92% of recovered infectious sf-HCVcc at a single density of
1.10 g/mL, following iodixanol gradient ultracentrifugation.
Furthermore, between 71% and 97% of infectious sf-HCVcc could
be recovered in three fractions with densities between 1.09 g/mL
and 1.12 g/mL (Fig. 5). Thus, infectious genotype 1–6 sf-HCVcc
constituted a more homogeneous virus population compared to
their HCVcc counterparts.
Infectious sf-HCVcc particles were apparently associated with ApoE
The altered density proﬁle of sf-HCVcc might indicate an
altered association with lipoproteins. To investigate if sf-HCVcc
was associated with ApoE, a key component of HCV associated
lipoproteins (Popescu and Dubuisson, 2010; Felmlee et al., 2013),
we carried out neutralization assays using a monoclonal antibody
directed against ApoE (Weisgraber et al., 1983; Chang et al., 2007).
Due to limited availability of this antibody, we studied only the
genotype 5a recombinant. SA13(5a) and sf-SA13(5a) showed a
similar concentration-dependent response with median inhibitory
concentrations (IC50) of 1.3 mg/mL for SA13(5a) and 1.1 mg/mL for
sf-SA13(5a), and almost complete neutralization achieved at the
highest α-ApoE concentrations (Fig. 6A), suggesting that genotype
5a HCVcc and sf-HCVcc showed similar association with ApoE.
These data were conﬁrmed by neutralizing SA13(5a) and sf-SA13
(5a) using anti-Apolipoprotein E antibody (ab24139, abcam). Using
this polyclonal rabbit IgG, complete neutralization, as well as 50%
neutralization, was observed at similar dilutions for SA13(5a) and
sf-SA13(5a) (data not shown).
We further carried out immunoprecipitation of SA13(5a) and
sf-SA13(5a) with the ApoE speciﬁc monoclonal antibody also used
for neutralization experiments in Fig. 6A (Weisgraber et al., 1983;
Chang et al., 2007). We observed no major differences in the
amount of viral RNA precipitated by this antibody (Fig. 6B).
Collectively, these data indicate that HCVcc and sf-HCVcc showed
similar association with ApoE.
Establishment of the use of sf-HCVcc in biological assays
To further characterize sf-HCVcc, we aimed at studying routes
of sf-HCVcc entry and sf-HCVcc sensitivity to neutralizing anti-
bodies. To avoid potential in vitro association of sf-HCVcc with FBS
components such as lipoproteins (Wünschmann et al., 2006), we
aimed at replacing DMEMþ10% FBS, typically used in such assays,
by AEM during the viral infection step. However, using AEM, in
initial experiments with genotypes 5a and 2a viruses, we found
greatly reduced infectivity for sf-SA13(5a) and sf-J6(2a). Interest-
ingly, SA13(5a) and J6(2a) infectivity was also reduced when these
viruses were diluted in AEM prior to infection (Fig. 7A and data not
shown). This loss of infectivity was not due to down-regulation of
important HCV co-receptors on AEM cultured Huh7.5 cells, since
expression of CD81, LDLr, SR-BI and claudin-1 was similar in
Huh7.5 cells cultured for three hours in either DMEMþ10% FBS
or AEM, as determined by ﬂow cytometry (Fig. 8).
To determine how infectivity of sf-HCVcc in AEM could be
rescued, we diluted sf-SA13(5a) in DMEMþ10% FBS (reference
culture), DMEM, AEM, or AEM supplemented with 10% FBS and/or
GlutaMax (a glutamine supplement present in DMEMþ10%
FBS culture medium but not in AEM). For sf-SA13(5a) diluted
in AEM, infectivity was only 12% of infectivity of the reference
culture (Fig. 7B). While supplementing AEM with GlutaMax did
not inﬂuence infectivity, supplementing AEM with 10% FBS or 10%
FBS and GlutaMax increased infectivity of sf-SA13(5a) to 67% and
68% respectively, compared to the reference culture (Fig. 7B).
When sf-SA13(5a) was diluted in DMEM without FBS (GlutaMax
only), infectivity was only 30% compared to the reference culture
(Fig. 7B). Apparently other FBS components than lipoproteins
and lipoprotein-associated factors mediated this enhancement
Table 1
Characteristics of genotype 1–6 sf-HCVcc virus stocks compared to HCVcc reference stocks.
Isolate (genotype)a Peak HCV Infectivity titerb Peak HCV RNA titerc Peak HCV Core titerd Speciﬁc infectivitye Speciﬁc infectivityf
log10 FFU/mL log10 IU/mL log10 amol Core/mL FFU/IU FFU/amol Core
sf-HCVcc HCVcc sf-HCVcc HCVcc sf-HCVcc HCVcc sf-HCVcc HCVcc sf-HCVcc HCVcc
H77(1a) 5.0 4.3 7.6 7.5 5.7 5.4 1/398 1/1,585 1/4.8 1/13.5
J4(1b) 4.7 3.2 7.5 7.3 5.6 5.1 1/631 1/12,589 1/8.1 1/79.8
J6(2a) 5.6 5.0 7.6 7.6 5.5 5.5 1/100 1/398 1/0.8 1/3.4
S52(3a) 4.9 4.3 7.4 7.2 5.5 5.4 1/316 1/794 1/3.8 1/12.5
ED43(4a) 4.7 3.6 7.1 7.6 5.0 5.4 1/251 1/10,000 1/2.0 1/58.0
SA13(5a) 6.2 4.1g 7.8 7.0 5.5 4.9 1/40 1/794 1/0.2 1/6.6
HK6a(6a) 5.6 4.0 7.7 7.0 5.6 4.8 1/126 1/1,000 1/0.9 1/5.9
Serum-free cultures were infected and maintained as described in “Materials and methods” section (Fig. 2). For sf-HCVcc, supernatant HCV infectivity titers, Core antigen,
and RNA titers were determined, and speciﬁc infectivities were calculated. Representative peak infectivity titers as well as Core and RNA titers from the same sample are
shown. Core-E2 sequences were determined by direct sequence analysis as described in “Materials and methods” section. For sf-J6(2a), sf-S52(3a), sf-ED43(4a), sf-SA13(5a)
and sf-HK6a(6a), Core-E2 sequences were identical to the plasmid sequence. The sf-H77(1a) had acquired the previously described amino acid change Y361H, estimated to
be present in 50% of viral genomes; this change was also present in the H77(1a) HCVcc stock shown in this table (Gottwein et al., 2009). The sf-J4(1b) had acquired amino
acid changes T578A and D584G, estimated to be present in the majority of viral genomes. For HCVcc, characteristics of references stocks are reproduced from Gottwein et al.
(2009).
a Isolate and genotype of Core-NS2 of the used JFH1-based recombinants is indicated. Recombinants are further described in “Materials and methods” section.
b For sf-HCVcc, supernatant infectivity titers were determined as FFU/mL by a cell culture-based titration assay as described in “Materials and methods” section. Values
are means of three replicates. For HCVcc, values are reproduced from Gottwein et al. (2009).
c For sf-HCVcc, supernatant RNA titers were determined in the samples, for which infectivity titers are given, as IU/mL by TaqMan PCR as described in “Materials and
methods” section. Values are means of two replicates. For HCVcc, values are reproduced from Gottwein et al. (2009).
d Core titers were determined in the samples, for which infectivity titers are given, as amol/mL using the ARCHITECT HCV Ag assay (Abbott).
e For sf-HCVcc, speciﬁc infectivity was calculated as FFU/IU by dividing supernatant infectivity titers with the corresponding RNA titers. For HCVcc, values were adapted
from Gottwein et al. (2009) to FFU/IU by dividing supernatant infectivity titers with the corresponding RNA titers.
f Speciﬁc infectivity was calculated as FFU/amol Core by dividing supernatant infectivity titers with the corresponding Core titers.
g The peak infectivity titer of this SA13(5a) reference stock was lower than what we typically observe. Typically, peak titers for SA13(5a) are 5 log10 FFU/mL (Fig. 3A).
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of infectivity, because supplementing AEM with either VLDL,
low density lipoprotein, high density lipoprotein, ApoB, ApoCI,
ApoE or water-soluble cholesterol did not rescue infectivity,
while lipoprotein deﬁcient FBS partly restored infectivity (data
not shown). Furthermore, we observed that sf-SA13(5a) infectivity
correlated with the % of FBS in AEM (Fig. 7C). These ﬁndings
suggested that yet undeﬁned factors in FBS culture medium
supplement were crucial for infectivity of HCVcc and sf-HCVcc.
Therefore, we investigated if sf-HCVcc was able to associate in vitro
with FBS components, leading to alteration of the observed sf-
HCVcc density proﬁle. We incubated sf-SA13(5a) with different
media and serum concentrations in the absence of cells. Such
incubations did not affect the density proﬁle of sf-SA13(5a) (Fig. 9),
suggesting that association between sf-HCVcc and serum
components did not occur to an extent that inﬂuenced the
previously observed density proﬁle (Fig. 5). Thus, it was feasible
to carry out further biological studies of sf-HCVcc in AEM supple-
mented with 10% FBS.
Entry of sf-HCVcc depended on HCV co-receptors CD81, LDLr
and SR-BI as well as on clathrin-mediated endocytosis
To investigate if sf-HCVcc differed from HCVcc regarding
entry into the host cell, we ﬁrst studied HCV co-receptors LDLr
and SR-BI, which might interact with lipoprotein components on
the LVP (Owen et al., 2009; Thi et al., 2012), as well as CD81,
supposed to directly interact with E2 (Pileri et al., 1998; McKeating
et al., 2004).
Fig. 3. Increased infectivity titers of serum-free cell cultures were not due to reduced cell-splitting, changes in cell viability or proliferation, or increased viral stability.
(A) AEM cultures produced higher infectivity titers than DMEMþ10% FBS cultures handled similarly and DMEMþ10% FBS control cultures. Huh7.5 cells were infected with
the SA13(5a) JFH1-based Core-NS2 recombinant in DMEMþ10% FBS for 3 h at an MOI of 0.003. On day 4 post-infection, cells were split into three replicate cultures.
Following day 6 post infection, when 80% of culture cells were infected, as determined by HCV NS5A immunostaining, one replicate culture was maintained in
DMEMþ10% FBS and split every 2–3 days, another replicate culture was maintained in DMEMþ10% FBS without being split, while the third replicate culture was maintained
in AEM without being split. At the indicated days post infection, supernatants were collected. Supernatant HCVcc infectivity titers are shown as means of 3 replicates with
standard error of the mean (SEM). The lower limit of detection in the experiment shownwas up to 2.6 log10 FFU/ml, indicated by y-axis break. nThe culture originally infected
with SA13(5a) was ﬁrst split into three replicates at day 4 post infection; thus, on days 1 and 4 post infection only one infectivity titer is shown. On day 6, DMEMþ10% FBS
supernatants were harvested from the three replicate cultures; subsequently cultures were maintained in the different growth media indicated. (B) AEM cultures showed
similar viability and proliferation as DMEMþ10% FBS cultures. Cell viability or proliferation of Huh7.5 cells cultured for 48 h in AEM versus DMEMþ10% FBS was determined
as described in “Materials and methods” section. The % viability/proliferation was calculated by relating absorbance at 490 nm (viability) or 450 nm (proliferation)
determined for AEM cultures to the mean absorbance of 10 replicate DMEMþ10% FBS cultures. Bars represent the means of 10 replicates with SEM. (C) sf-HCVcc and HCVcc
showed similar freeze-thaw stability. SA13(5a) diluted 1:100 in DMEMþ10% FBS or sf-SA13(5a) diluted 1:100 in either AEM or AEMþ10% FBS were exposed to up to 5 freeze/
thaw cycles. Samples were thawn at room temperature and frozen at 80 1C. After the indicated number of cycles, infectivity titers were determined as described in
“Materials and methods” section. The % infectivity was calculated by relating the infectivity titer of each sample to the mean titer of a reference sample of the same stock,
which had been stored at 80 1C. Bars represent the means of three replicates with SEM. (D) sf-HCVcc showed decreased stability under temperature stress. SA13(5a)
diluted 1:100 in DMEMþ10% FBS or sf-SA13(5a) diluted 1:100 in either AEM or AEMþ10% FBS were incubated at 4 1C, room temperature (RT) or 37 1C for 4–48 h as
indicated. Infectivity titers were determined as described in “Materials and methods” section. The % infectivity was calculated by relating the infectivity titer of each sample
to the mean titer of a reference sample of the same stock, which had been stored at 80 1C. Bars represent the means of three replicates with SEM. The lower limit of
detection in the experiment shown was up to 2%, indicated by y-axis break.
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When blocking CD81, for genotype 1–6 HCVcc, maximum
blocking rates (Bmax) of 100% were observed at the highest α-
CD81 concentrations; for these viruses, similar blocking rates were
previously observed (Gottwein et al., 2009). Genotype 1–6 sf-
HCVcc showed similar concentration-dependent sensitivity
towards CD81 blocking as their HCVcc counterparts (Fig. 10, left
column).
When blocking LDLr, we found concentration-dependent
blocking for genotype 1–6 HCVcc. Bmax values were between
69% for ED43(4a) and 100% for SA13(5a) at the highest concen-
trations of α-LDLr, suggesting genotype/isolate-speciﬁc differ-
ences in dependency on LDLr (Fig. 10, middle column).
Genotype 1–6 sf-HCVcc could also be blocked in a
concentration-dependent manner, with Bmax values between
33% for sf-HK6a(6a) and 74% for sf-H77(1a) at the highest
concentrations of α-LDLr. While sf-H77(1a), sf-S52(3a) and sf-
ED43(4a) showed similar Bmax values as their HCVcc counter-
parts, sf-J4(1b), sf-J6(2a), sf-SA13(5a) and sf-HK6a(6a) showed
31–55% lower Bmax values than their HCVcc counterparts, sug-
gesting that sf-HCVcc of certain genotypes had lower depen-
dency on LDLr than their HCVcc counterparts.
Blocking of SR-BI had only limited effect on entry of J4(1b) and
HK6a(6a) HCVcc with Bmax values o50% (Fig. 10, right column).
For HCVcc of other genotypes we observed concentration-
dependent blocking with Bmax values between 51% for J6(2a) and
80% for H77(1a) at the highest concentrations of α-SR-BI. Thus,
sensitivity to SR-BI blocking apparently depended on the geno-
type/isolate. Blocking of SR-BI also had limited effect on entry of
sf-J4(1b) and sf-HK6a(6a). Entry of sf-HCVcc of other genotypes
was blocked in a concentration-dependent manner, with Bmax
values between 60% for sf-SA13(5a) and 86% for sf-H77(1a). Bmax
values were similar between HCVcc and sf-HCVcc of the same
genotype. Thus, overall, HCVcc and sf-HCVcc of the same genotype
showed similar sensitivity to SR-BI blocking.
Finally, we studied dependency of genotype 1–6 sf-HCVcc on
clathrin-mediated endocytosis. When pre-treating cells with
chlorpromazine, we observed concentration-dependent blocking
rates of up to 93%, suggesting that both sf-HCVcc and HCVcc
depended on clathrin-mediated endocytosis (Fig. 11A–G). We were
not able to achieve 100% blocking for any of the recombinants at
10 μg/mL chlorpromazine, the highest concentration not resulting
in cytotoxic effects (Fig. 11H). Interestingly, most sf-HCVcc were
slightly more sensitive to chlorpromazine treatment than their
HCVcc counterparts. This difference was greatest for J4(1b), ED43
(4a) and HK6a(6a). For J6(2a) and SA13(5a) no obvious difference
was observed, while H77(1a) and S52(3a) showed relatively small
differences. This suggested that dependency on clathrin-mediated
endocytosis might be slightly greater for sf-HCVcc of most geno-
types/isolates than for HCVcc.
In conclusion, these data suggest that, overall, entry of HCVcc
and sf-HCVcc relied on CD81, LDLr and SR-BI HCV co-receptors as
well as on clathrin-mediated endocytosis, with exception of
genotype 1b and 6a particles, which could not be blocked by
α-SR-BI. However, we detected minor differences for recombinants
of different HCV genotypes and for HCVcc versus sf-HCVcc
regarding dependency on certain receptors and clathrin-
mediated endocytosis
Chronic-phase patient sera and monoclonal antibodies against
conformational epitopes in E1E2 and E2 neutralized sf-HCVcc
To investigate if there were differences between HCVcc and sf-
HCVcc in sensitivity to neutralizing antibodies, we ﬁrst did
neutralization of genotype 1–6 viruses using serum from genotype
1a infected Patient H, taken 29 years after acute infection (H06
(Scheel et al., 2008)). For HCVcc, as previously described, S52(3a)
was the least sensitive to neutralization with H06 (Fig. 12D)
(Scheel et al., 2008; Gottwein et al., 2009; Prentoe et al., 2011).
For HCVcc of other genotypes we observed dilution-dependent
neutralization with IC50 values ranging from 1/1,436 to 1/233,209
and relatively high neutralization rates by high concentrations of
H06 serum (Fig. 12). For genotype 1–6 sf-HCVcc, we found similar
neutralization patterns as for their HCVcc counterparts. For all sf-
HCVcc except S52(3a) we observed dilution dependent neutraliza-
tion with IC50 values ranging from 1/605 to 1/156,666 and
relatively high neutralization rates by high concentrations of H06
serum (Fig. 12). Thus, sf-HCVcc particles showed similar suscept-
ibility to neutralizing antibodies in chronic phase patient serum
as HCVcc.
To conﬁrm these observations, we next neutralized SA13(5a)
and sf-SA13(5a) with a genotype 5a chronic-phase patient serum
(SA3 (Jensen et al., 2008)). These viruses showed similar neutra-
lization proﬁles, with IC50 values of 1/928 for SA13(5a) and 1/654
for sf-SA13(5a) as well as high neutralization rates by high
concentrations of SA3 serum (Fig. 13A).
Finally, we tested a panel of monoclonal antibodies (AR1B and
AR2A-5A) targeting deﬁned conformational epitopes in E1E2 and
E2 (Law et al., 2008; Giang et al., 2012), against SA13(5a) and sf-
SA13(5a). AR1B was the least efﬁcient for both viruses without
reaching a top plateau (Fig. 13B). AR2A-5A neutralized SA13(5a)
and sf-SA13(5a) with similar concentration–response proﬁles,
with IC50 values ranging from 0.33 to 0.53 μg/mL for SA13(5a)
and 0.19–1.56 μg/mL for sf-SA13(5a); for both viruses complete
neutralization was observed at high antibody concentrations
(Fig. 13C–F). This further supports that sf-HCVcc have similar
Fig. 4. Serum-free culture decreased viral replication/translation but enhanced
viral release and speciﬁc infectivity. S29 cells were transfected with SA13(5a) as
well as positive control (J6(2a)) and negative control (J6(2a)-GND) HCV RNA
transcripts as described in “Materials and methods” section. (A) Intracellular (black
bars) and extracellular (gray bars) Core levels were determined 24, 48 and 72 h
post transfection. Core levels were normalized to intracellular Core levels measured
4 h post transfection. (B) Intracellular (black bars) and extracellular (gray bars)
infectivity titers were determined 24, 48 and 72 h post transfection. Intracellular
infectivity titers are shown as the means (FFU/well) of three replicates with SEM.
Extracellular infectivity titers are shown as the means (FFU/mL) of three replicates
with SEM. The lower limits of detection are indicated by y-axis breaks.
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sensitivity to neutralizing antibodies as HCVcc. In addition, these
ﬁndings suggest that sf-HCVcc and HCVcc do not show major
differences regarding conformation of E1 and E2.
Discussion
In this study, we describe the generation and characterization
of genotype 1–6 serum-free HCVcc particles, using AEM to
culture infected Huh7.5 hepatoma cells. Compared to HCVcc, sf-
HCVcc showed similar biological properties but increased infec-
tivity titers and a homogenous single-peak density proﬁle. These
unique characteristics, as well as the reduced concentration of
non-HCV proteins in serum-free culture supernatants, are
expected to facilitate generation of puriﬁed and concentrated
virus stocks, required for vaccine development and biophysical
studies of HCV particle composition (Gastaminza et al., 2010;
Merz et al., 2010; Catanese et al., 2013; Akazawa et al., 2013).
Further, the developed serum-free culture conditions might
reduce the risk of contamination with adventitious microbial
Fig. 5. The sf-HCVcc particles of genotype 1–6 displayed an altered density proﬁle with a single infectivity peak. Of the virus stocks described in Fig. 2, 10 mL HCVcc
supernatant taken from the last harvest of DMEMþ10% FBS culture supernatant (black line) or 10 mL sf-HCVcc supernatant taken after 48 h of AEM culture (gray, dotted
line) was concentrated and layered on top of a pre-formed 10–40% iodixanol gradient and subjected to ultracentrifugation as described in “Materials and methods” section.
Fractions were collected from the bottom of the gradients and analyzed by infectivity titration and by density determination as described in “Materials and methods” section.
The HCV Core-E2 sequences of all virus stocks used were determined by direct sequencing. Compared to the plasmid sequence, sf-H77(1a) and H77(1a) had acquired the
previously described amino acid change Y361H (Gottwein et al., 2009), estimated to be present in 50% of viral genomes. The sf-J4(1b) had acquired amino acid changes
T578A and D584G, estimated to be present in the majority of viral genomes. Relative recovery per fraction (%) was calculated by relating the amount of infectious virus
detected in each fraction to the total amount of infectious virus collected, and is plotted against the density determined for each fraction.
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Fig. 6. HCVcc and sf-HCVcc showed similar association with ApoE. (A) Monoclonal α-ApoE antibody (1D7) and control mouse IgG1κ (1D1) were diluted in DMEMþ10% FBS
to the indicated concentrations. SA13(5a) (black circles) and sf-SA13(5a) (gray squares) were diluted in DMEMþ10% FBS and incubated with dilutions of α-ApoE or mouse
IgG1κ for 30 min at 37 1C. The virus–antibody mixes were added to Huh7.5 cells, plated the previous day in poly-D-lysine coated 96 well plates. After 3 h of incubation, virus–
antibody mixes were removed and DMEMþ10% FBS was added. Cells were ﬁxed 48 h post infection and stained, and the number of single HCV NS5A positive cells per well
was determined by automated counting as described in “Materials and methods” section. The % neutralization was calculated by relating counts of experimental wells to the
mean count of six replicate wells with untreated control virus. Data points are means of three replicates with SEM (error bars). Following logarithmic transformation of
X-values, variable-slope sigmoidal dose–response curves were ﬁtted [Y¼Bottomþ(Top–Bottom)/(1þ10(Log10EC50X)HillSlope)]. “Bottom” was constrained to “0”. “Top” was
constrained to “100”. (B) Immunoprecipitation was carried out on 106 IU HCV RNA of SA13(5a) (black bars) and sf-SA13(5a) (gray bars), using monoclonal α-ApoE (1D7) and
control mouse IgG1κ (1D1) as described in “Materials and methods” section. Amounts of HCV RNA (IU) were determined in the immunoprecipitated fractions using TaqMan
PCR as described in “Materials and methods” section. RNA titers are shown as the mean of two replicates with SEM.
Fig. 7. FBS enhances infectivity of both HCVcc and sf-HCVcc. (A–C) Huh7.5 cells seeded in poly-D-lysine coated 96-well plates the previous day, were incubated with (A) SA13
(5a) and sf-SA13(5a) diluted in DMEMþ10% FBS (black bars) or AEM (gray bars), (B) sf-SA13(5a) diluted in different media with supplements as indicated or (C) sf-SA13(5a)
diluted in AEM supplemented with different concentrations of FBS. % FBS in growth medium indicates the ﬁnal FBS concentration. (A–C) Cells were incubated with virus
mixes for 3 h. After incubation, fresh DMEMþ10% FBS was added to all wells. Cells were incubated for 48 h before they were ﬁxed, stained and the number of single HCV
NS5A positive cells per well was determined by automated counting as described in “Materials and methods” section. Error bars represent SEM of triplicates. For (B), the
mean infectivity (HCV NS5A positive cells/well) of triplicate wells of the reference culture (DMEMþ10% FBS, black bar) was set to 100%. The number of HCV NS5A positive
cells/experimental well was related to this mean to calculate % infectivity relative to the reference culture.
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agents in future vaccine antigen preparations (WHO, 1998;
Houghton et al., 2013).
Efﬁcient production of HCVcc has primarily been achieved in
the continuous hepatoma cell line Huh7 and derived cell lines, such
as Huh7.5 cells (Steinmann and Pietschmann, 2013; Lohmann and
Bartenschlager, 2014). Due to their increased permissiveness to
infection with recombinant HCV, Huh7.5 cells were previously used
for cell culture adaptation and growth of HCV genotype 1–6
recombinants used in this study (Lindenbach et al., 2005;
Gottwein et al., 2007; Scheel et al., 2008; Jensen et al., 2008;
Gottwein et al., 2009). According to WHO recommendations, a
wide range of continuous cell lines are now considered as suitable
substrates for production of various medicinal substances if certain
requirements are met (WHO, 1998). These requirements include
use of well-characterized cell banks, use of suitable manufacturing
procedures aiming at a high degree of puriﬁcation of the end
product, and thorough characterization of the end product (WHO,
1998). Thus, Huh7.5 cells could potentially be characterized to
comply with these recommendations, allowing their use for
vaccine development. Huh7 derived cell lines have typically
been subjected to long-term passage using serum-containing
growth medium and animal-derived trypsin. According to WHO
recommendations, animal derived products should be reduced or
eliminated from cell cultures used for production of medicinal
substances due to risk of contamination with adventitious micro-
bial agents (WHO, 1998). In this study, we describe a method for
production of sf-HCVcc, thus avoiding the use of trypsin and bovine
serum during the virus production phase. To further reduce
presence of animal-derived components in sf-HCVcc producing
cell culture, it might be possible to culture Huh7.5 cells in serum-
free medium (Nakabayashi et al., 1982), prior to sf-HCVcc produc-
tion. Alternatively, based on recently generated knowledge on
host-factors required for HCV infection, it might be possible to
engineer cell lines already approved for vaccine development with
susceptibility to HCV infection (Narbus et al., 2011; Costa et al.,
2012; Kambara et al., 2012; Vogt et al., 2013; Sourisseau et al.,
2013; Frentzen et al., 2014). However, this might be a cumbersome
process and might require re-approval of the modiﬁed cell-line. Of
note, most genotype 1–6 recombinants used in this study
(Lindenbach et al., 2005; Gottwein et al., 2007; Scheel et al.,
2008; Jensen et al., 2008; Gottwein et al., 2009) contained adaptive
mutations conferring efﬁcient growth in Huh7.5 cells; for HK6a(6a)
cell culture adaptive mutations localized to the envelope proteins.
In addition, in this study H77(1a) and J4(1b) polyclonal virus stocks
Fig. 8. Huh7.5 cells cultured in DMEMþ10% FBS or AEM showed similar surface expression of HCV co-receptors. Huh7.5 cells were incubated for 3 h in DMEMþ10% FBS or
AEM and subsequently prepared for ﬂow cytometry analysis as described in “Materials and methods” section. Cell surface expression of HCV co-receptors was determined
using antibodies against (A) CD81, (B) LDLr, (C) SR-BI and (D) claudin-1 as described in “Materials and methods” section. Phycoerythrin (PE) signals were recorded on a BD
FACSCalibur ﬂow cytometer. Histograms show the co-receptor surface expression in cells cultured in DMEMþ10% FBS (dark blue) or AEM (light blue) compared to unstained
cells (black and gray, respectively).
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had acquired putative cell culture adaptive mutations in the
envelope proteins. In future studies, it will be of relevance to
develop a panel of genotype 1–6 recombinants without envelope
mutations, thus not differing from naturally occurring isolates.
Recently, proof-of-concept for immunogenicity of genotype 2a
HCVcc was obtained, since immunization of mice resulted in
induction of HCV neutralizing antibodies (Akazawa et al., 2013;
Houghton et al., 2013; Gottwein and Bukh, 2013). This underlines
the potential of inactivated HCVcc particles as future vaccine
antigens. However, HCVcc used for immunizations were grown in
cell culture medium supplemented with 2% FBS (Akazawa et al.,
2013), even though the authors had previously reported develop-
ment of serum-free cultures for genotype 2a recombinants JFH1 and
J6/JFH1, using growth medium DMEM/F-12 supplemented with
Insulin–Transferrin–Selenium-X (Akazawa et al., 2011). In contrast
to our study, infectivity titers and speciﬁc infectivity of 2a virus from
such serum-free cultures were apparently only equal to or lower
than titers of viruses from serum-supplemented cultures (Akazawa
et al., 2011). In addition, serum-free 2a HCVcc showed a similar
density proﬁle as 2a HCVcc derived from serum-containing cell
culture, following sucrose gradient ultracentrifugation (Akazawa
et al., 2011). These differences between previously produced
serum-free 2a HCVcc (Akazawa et al., 2011) and sf-HCVcc described
in this study are most likely due to the different culture media used
and/or other differences in experimental conditions.
We describe establishment of serum-free cell cultures producing
HCV particles of prototype strains of genotypes 1–6 with favorable
biophysical and biological characteristics (Figs. 2 and 5 and Table 1)
(Gottwein et al., 2009; Bukh et al., 2010). Supernatant infectivity
titers of sf-HCVcc were 0.6–2.1 log10 FFU/ml higher than titers of
HCVcc (Table 1 and Fig. 2) (Gottwein et al., 2009). Of the panel of
previously developed HCVcc recombinants (Gottwein et al., 2009),
SA13(5a) showed the highest infectivity titers (5 log10 FFU/ml).
Infectivity titers of 46 log10 FFU/ml, as observed for sf-SA13(5a)
(Table 1 and Fig. 2F and 3A), are among the highest infectivity titers
reported to date for cell culture grown HCV (Russell et al., 2008;
Dhillon and Witteveldt, 2010; Pokrovskii et al., 2011; Liu et al., 2012;
Jiang and Luo, 2012; Horwitz et al., 2013). Furthermore, recombinants
with relatively low infectivity titers, such as J4(1b) and ED43(4a)
(Scheel et al., 2008; Gottwein et al., 2009), yielded signiﬁcantly
increased infectivity titers, when grown under serum-free conditions
(Table 1 and Fig. 2B and E). Genotype 1b is considered to be the most
prevalent genotype worldwide and in certain countries, such as
Egypt, genotype 4a has a prevalence of up to 15%; thus genotype 4a
sf-HCVcc might prove to be an important antigen for vaccine trials
(Abdo and Lee, 2004; Simmonds et al., 2005). The reason why
serum-free culture conditions resulted in increased infectivity titers
remains to be fully elucidated. Our studies indicated that increased
infectivity in AEM cultures was not due to (i) avoiding stress related
to cell splitting (Fig. 3A), (ii) changes in Huh7.5 cell viability or
proliferation (Fig. 3B) or (iii) increased stability of sf-HCVcc (Fig. 3C
and D). While in S29 cells, serum-free culture conditions resulted in
reduction of viral replication/translation, they increased viral release
and speciﬁc infectivity, possibly contributing to the higher infectivity
titers observed (Fig. 4).
Speciﬁc infectivities were generally higher for sf-HCVcc than
for HCVcc as observed in both Huh7.5 cell cultures (Table 1) and
S29 cell cultures (Fig. 4). This is in line with previous reports that
HCVcc fractions with the highest speciﬁc infectivity had a buoyant
density between 1.09 and 1.10 g/mL (Lindenbach et al., 2005),
similar to the density of the majority of infectious sf-HCVcc
particles (Fig. 5). Higher speciﬁc infectivity might be due to
absence of serum, which might have non-speciﬁc neutralizing or
inhibitory activity; alternatively, less immature viral particles
might be produced using the developed culture conditions.
Furthermore, in our serum-free cultures, supernatants with
high infectivity titers could typically be harvested for a prolonged
period of time compared to DMEMþ10% FBS cultures (Figs. 1–4).
For example, for SA13(5a), high-titer supernatants could typically
be harvested at 2–3 subsequent time points in DMEMþ10% FBS
cultures, whereas in serum-free cultures, high-titer supernatants
could be harvested at 4–6 subsequent time points (Figs. 2F and
3A). This further increased the yield of infectious virus that could
be harvested from serum-free cultures.
In contrast to HCVcc, sf-HCVcc displayed a homogeneous
density distribution with a single peak of infectious virus at
densities of 1.10 g/mL, following iodixanol gradient ultracentri-
fugation (Fig. 5). We believe that the density proﬁle of sf-HCVcc
might allow more effective density-based puriﬁcation and con-
centration using ultracentrifugation and gel chromatography,
since a single fraction, containing the majority of infectious virus,
could be collected. Density changes were previously observed for
HCVcc without hypervariable region 1 (HVR1) (Bankwitz et al.,
2010; Prentoe et al., 2011), HCVcc with a speciﬁc E2 mutation
(Zhong et al., 2006; Grove et al., 2008; Gastaminza et al., 2010) and
for HCV recovered from HCVcc-infected chimpanzees and uPA-
SCID mice engrafted with human liver cells (Lindenbach et al.,
2006). These density changes were suggested to be due to
differences in lipoprotein association (Lindenbach et al., 2006;
Zhong et al., 2006; Grove et al., 2008; Bankwitz et al., 2010;
Prentoe et al., 2011). We showed that sf-SA13(5a) could be
neutralized as efﬁciently as its HCVcc counterpart by a monoclonal
α-ApoE antibody and polyclonal α-ApoE IgG (Fig. 6A and data not
shown). Further, immunoprecipitation of sf-SA13(5a) and SA13(5a)
showed similar efﬁcacy (Fig. 6B). These data indicate that HCVcc
and sf-HCVcc do not show major differences in association to
ApoE, and thus possibly to lipoproteins (Yamamoto et al., 2011).
Therefore, further studies will be required to elucidate the cause
for the observed density shift (Fig. 5). Preliminary studies
indicated a decrease in intracellular lipid content in serum-free
Fig. 9. The sf-HCVcc density proﬁle was maintained after in vitro incubation with
serum. The sf-SA13(5a) was mixed 1:1 with either 100% FBS, DMEMþ10% FBS,
DMEM, AEM, 100% human serum or sterile ﬁltered cell culture conditioned
medium (DMEMþ10% FBS harvested after 48 h culture on naïve Huh7.5 cells)
and incubated for 6 h at 37 1C. Mixes were layered on top of a pre-formed 10–40%
iodixanol gradient, and subjected to ultracentrifugation as described in “Materials
and methods” section. Fractions were collected from the bottom of the gradients
and analyzed by infectivity titration and by density determination as described in
“Materials and methods” section. Relative recovery per fraction (%) was calculated
by relating the amount of infectious virus detected in each fraction to the total
amount of infectious virus collected, and is plotted against the density determined
for each fraction.
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cultures (data not shown). However, determination of expression
levels of genes involved in lipid production or of lipid/lipoprotein
composition of HCVcc versus sf-HCVcc (Merz et al., 2010) was
considered outside the scope of this study.
Compared to HCVcc, HCVcc without HVR1, displaying a similar
density distribution as sf-HCVcc, were less susceptible to blocking
of SR-BI and more susceptible to neutralizing antibodies (Bankwitz
et al., 2010; Prentoe et al., 2011; Prentoe et al., 2014). Furthermore,
Fig. 10. Effect of co-receptor blocking on HCVcc and sf-HCVcc entry. α-CD81 (left column), α-LDLr (middle column) or α-SR-BI (right column) was diluted in DMEMþ10%
FBS to the indicated concentrations. Speciﬁed antibody (open symbols) or control antibody (closed symbols) dilutions were added to Huh7.5 cells, plated the previous day
onto poly-D-lysine coated 96-well plates and incubated for 1 h. HCVcc (black circles) were diluted in DMEMþ10% FBS and sf-HCVcc (gray squares) were diluted in AEMþ10%
FBS and added to cultures. After 6 h incubation, antibody–virus mixes were removed and DMEMþ10% FBS was added. Cells were ﬁxed 48 h post infection and stained, and
the number of single HCV NS5A positive cells per well was determined by automated counting as described in “Materials and methods” section. The HCV Core-E2 sequences
of all virus stocks used were determined by direct sequencing. Sequences were identical for HCVcc and sf-HCVcc of the same recombinant. Compared to the plasmid
sequence, H77(1a) viruses had acquired amino acid change I348S and J4(1b) had acquired amino acid change V710L, both estimated to be present in the majority of viral
genomes. The % blocking was calculated by relating counts of experimental wells to the mean count of six replicate wells with untreated control virus. Data points are means
of three replicates with SEM (error bars). Following logarithmic transformation of X-values, variable-slope sigmoidal dose–response curves were ﬁtted [Y¼Bottomþ(Top–
Bottom)/(1þ10(Log10EC50X)HillSlope)]. “Bottom” was constrained to “0”. Bmax values, the Y values at the top plateaus of the ﬁtted curves, are shown for HCVcc (black) and sf-
HCVcc (gray). No curve could be ﬁtted to data points obtained for sf-HK6a(6a) in SR-BI blocking experiments. ND, not determinable.
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previously described serum-free HCVcc were more susceptible to
blocking of CD81 and SR-BI and to neutralization by a monoclonal
antibody targeting E2 (AP33) (Akazawa et al., 2011). Of note, in this
study biological assays were carried out in AEM supplemented with
FBS, which was required for viral infection, but apparently did not
alter composition of sf-HCVcc LVP (Figs. 7 and 9). When blocking
CD81 and SR-BI, we did not observe major differences between sf-
HCVcc and HCVcc (Fig. 10). Even though sf-HCVcc of certain
genotypes showed slightly lower dependency on LDLr and slightly
higher dependency on clathrin mediated endocytosis than their
HCVcc counterparts (Figs. 10 and 11), overall our ﬁndings suggested
that sf-HCVcc relied on similar routes of entry as HCVcc. In the future,
it will be of interest to further investigate the small differences
observed for LDLr usage and dependency on clathrin mediated
endocytosis using different blocking antibodies and alternative
methods of inhibition such as RNA interference.
We further conﬁrmed previous results showing that HCVcc of
genotype 1–6 showed similar dependency on CD81 (Gottwein
et al., 2009). Previously, we reported that blocking SR-BI had a
similar effect on genotype 1–6 HCVcc entry (Gottwein et al., 2009).
However, in this study and another recent study by our group
(Prentoe et al., 2014), using a different blocking antibody, we
Fig. 11. Effect of chlorpromazine treatment on HCVcc and sf-HCVcc entry. (A–G) Chlorpromazine was diluted in DMEMþ10% FBS to the concentrations indicated and then
added to Huh7.5 cells, plated the previous day onto poly-D-lysine coated 96-well plates, and incubated for 30 min. HCVcc (black bars) were diluted in DMEMþ10% FBS and
sf-HCVcc (gray bars) were diluted in AEMþ10% FBS and added to cultures. After 6 h incubation, chlorpromazine–virus mixes were removed and DMEMþ10% FBS was added.
Cells were ﬁxed 48 h post infection and stained, and the number of single HCV NS5A positive cells per well was determined by automated counting as described in “Materials
and methods” section. The HCV Core-E2 sequences of all virus stocks used were determined by direct sequencing. Sequences were identical for HCVcc and sf-HCVcc of the
same recombinant. Compared to the plasmid sequence, H77(1a) viruses had acquired amino acid change I348S and J4(1b) had acquired amino acid change V710L, both
estimated to be present in the majority of viral genomes. The % blocking was calculated by relating counts of experimental wells to the mean count of six replicate wells with
untreated control virus. Data points are means of three replicates with SEM (error bars). n,Valueso0. (H) Chlorpromazine was diluted in DMEMþ10% FBS to the
concentrations indicated and then added to Huh7.5 cells, plated the previous day in poly-D-lysine coated 96-well plates. Cells were incubated for 6 h before chlorpromazine
was removed and DMEMþ10% FBS was added. A cell viability assay was carried out on cells incubated for 6 h with chlorpromazine and on control cultures as described in
“Materials and methods” section (0 h post treatment; dashed bars). An additional cell viability assay was carried out on chlorpromazine treated- and control cultures 48 h
post treatment (white bars). The % viability was calculated by relating absorbance at 490 nm determined for chlorpromazine treated cultures to the mean absorbance of
three replicate untreated cultures. Bars represent the means of three replicates with SEM.
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found differential sensitivity of genotype 1–6 HCVcc to SR-BI
blocking. Single E2 mutations in culture adapted JFH1(2a) were
reported to cause reduced dependency on SR-BI (Grove et al.,
2008; Dhillon and Witteveldt, 2010). Further studies are required
to elucidate if the E2 mutations present in HK6a(6a) and J4(1b)
HCVcc virus stocks mediated reduced dependency on SR-BI. For
genotype 1–6 HCVcc, we also observed small but consistent
differences regarding dependency on LDLr (Fig. 10). Whereas
dependency on LDLr for entry has been shown for JFH1(2a)
(Owen et al., 2009; Albecka et al., 2012) and was recently shown
for H77(1a), J6(2a) and S52(3a) HCVcc (Prentoe et al., 2014), this
study is the ﬁrst to show dependency on LDLr for J4(1b), ED43(4a),
SA13(5a) and HK6a(6a) HCVcc. In future studies, also involving
recombinants of additional isolates of each genotype, it will be of
interest to investigate if different genotypes, subtypes or isolates
differ regarding receptor usage.
Compared to HCVcc, sf-HCVcc showed similar sensitivity to
neutralization by chronic phase patient sera and human mono-
clonal antibodies targeting conformational epitopes in E1E2 and
E2 (Figs. 12 and 13). These results suggest that sf-HCVcc resemble
Fig. 12. HCVcc and sf-HCVcc show similar sensitivity to neutralization with genotype 1a chronic-phase patient serum. Genotype 1a serum H06 was diluted in DMEMþ10%
FBS as indicated. HCVcc (black circles) were diluted in DMEMþ10% FBS and sf-HCVcc (gray squares) were diluted in AEMþ10% FBS, mixed with H06 serum dilutions and
incubated 1 h at 37 1C. Virus–serum mixes were added to Huh7.5 cells, plated the previous day onto poly-D-lysine coated 96 well plates. After 6 h incubation, virus–serum
mixes were removed and DMEMþ10% FBS was added. Cells were ﬁxed 48 h post infection and stained, and the number of single HCV NS5A positive cells per well was
determined by automated counting as described in “Materials and methods” section. The HCV Core-E2 sequences of all virus stocks used were determined by direct
sequencing. Sequences were identical for HCVcc and sf-HCVcc of the same recombinant. Compared to the plasmid sequence, H77(1a) viruses had acquired amino acid
change I348S and J4(1b) had acquired amino acid change V710L, both estimated to be present in the majority of viral genomes. The % neutralization was calculated by
relating counts of experimental wells to the mean count of six replicate wells with untreated control virus. Data points are means of three replicates with SEM (error bars).
Following logarithmic transformation of X-values, variable-slope sigmoidal dose–response curves were ﬁtted [Y¼Bottomþ(Top–Bottom)/(1þ10(Log10EC50X)HillSlope)].
“Bottom” was constrained to “0” for all curves. “Top” was constrained to “100” for all curves in all panels except D; for these curves, median inhibitory concentrations (IC50)
were calculated (black for HCVcc and gray for sf-HCVcc). ND, not determinable.
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HCVcc regarding epitope exposure and conformation, of impor-
tance for vaccine development using sf-HCVcc as antigen.
In conclusion, we have established a method allowing for
robust production of genotype 1–6 sf-HCVcc with favorable
biological and biophysical characteristics. Serum-free culture
apparently reduced viral replication/translation but enhanced viral
release and speciﬁc infectivity. Sf-HCVcc had increased infectivity
titers compared to HCVcc, and compared to serum-free HCVcc
reported previously, thus contributing to an increased yield of
infectious virus from infected cell cultures. Furthermore, sf-HCVcc
displayed a homogeneous density distribution. Together with a
reduced concentration of non-HCV proteins in supernatants from
serum-free cultures, these features are expected to facilitate viral
puriﬁcation and concentration required for vaccine production
and morphological analysis of HCV particles. Biologically, sf-HCVcc
particles resembled their HCVcc counterparts regarding associa-
tion to ApoE, routes of viral entry and sensitivity to neutralizing
antibodies. Thus, sf-HCVcc particles could prove important as
antigens in a prophylactic HCV vaccine against all six epidemiolo-
gically important HCV genotypes. To this aim future studies are
required, focussing on establishment of large-scale sf-HCVcc
production as well as efﬁcient puriﬁcation, concentration and
inactivation. Finally, it will be of great interest to test immuno-
genicity of genotype 1–6 sf-HCVcc in small animal models.
Materials and methods
Huh7.5 cell culture and infection with HCV recombinants
Human hepatoma Huh7.5 cells were cultured in culture ﬂasks
(Nunc) in DMEM (Gibco/Invitrogen) supplemented with 10% fetal
bovine serum (FBS, [Sigma]), penicillin 100 U/mL and streptomycin
100 mg/mL (Gibco/Invitrogen), referred to as DMEMþ10% FBS.
Cells were kept sub-conﬂuent and split every 2–3 days. For
splitting, cells were washed in PBS (Invitrogen) and detached
using trypsin (Sigma-Aldrich). For serum-free cultures, cells were
plated in DMEMþ10% FBS. When cells were 80% conﬂuent,
DMEMþ10% FBS was removed, cells were washed in PBS and
adenovirus expression medium (AEM, [Gibco/Invitrogen]) supple-
mented with penicillin 100 U/mL and streptomycin 100 mg/mL,
referred to as AEM, was added without splitting the cells. Every 2–
3 days, supernatant was removed and fresh AEM was added to the
cells. Huh7.5 cell cultures were maintained at 37 1C and 5% CO2.
Fig. 13. SA13(5a) and sf-SA13(5a) show similar susceptibility to genotype 5a patient serum and human monoclonal antibodies. (A) Genotype 5a chronic phase serum SA3 or
(B–F) monoclonal antibodies AR1B and AR2A-5A were diluted in DMEMþ10% FBS as indicated. HCVcc (black circles) were diluted in DMEMþ10% FBS and sf-HCVcc (gray
squares) were diluted in AEMþ10% FBS, mixed with SA3 serum, AR1B or AR2A-5A antibody dilutions and incubated 1 h at 37 1C. Virus–serum or virus–antibody mixes were
added to Huh7.5 cells, plated the previous day in poly-D-lysine coated 96 well plates. After 6 h incubation, virus–serum or virus–antibody mixes were removed and
DMEMþ10% FBS was added. Cells were ﬁxed 48 h post infection and stained, and the number of single HCV NS5A positive cells per well was determined by automated
counting as described in “Materials and methods” section. The % neutralization was calculated by relating counts of experimental wells to the mean count of six replicate
wells with untreated control virus. Data points are means of three replicates with SEM (error bars). Following logarithmic transformation of X-values, variable-slope
sigmoidal dose–response curves were ﬁtted [Y¼Bottomþ(Top–Bottom)/(1þ10(Log10EC50X)HillSlope)]. “Bottom” was constrained to “0” for all curves. “Top” was constrained to
“100” for all curves. Median inhibitory concentrations (IC50) were calculated (black for HCVcc and gray for sf-HCVcc).
C.K. Mathiesen et al. / Virology 458-459 (2014) 190–208204
Generation of HCVcc virus stocks
For generation of HCVcc and sf-HCVcc virus stocks, Huh7.5 cells
cultured in DMEMþ10% FBS at 80% conﬂuency were infected at a
multiplicity of infection (MOI) of 0.003 using 1st or 2nd viral
passage stocks of the following HCVcc intra- and intergenotypic
recombinants: H77C/JFH1V787A,Q1247L (referred to as H77(1a)),
J4/JFH1F886L,Q1496L (J4(1b)), J6/JFH1 (J6(2a)), S52/JFH1I787S,K1398Q
(S52(3a)), ED43/JFH1T827A,T977S (ED43(4a)), SA13/JFH1A1022G,K1119R
(SA13(5a)), and HK6a/JFH1F350S,N417T (HK6a(6a)) (Lindenbach et al.,
2005; Gottwein et al., 2007; Scheel et al., 2008; Jensen et al., 2008;
Gottwein et al., 2009). The % infection was monitored by HCV-
speciﬁc immunostaining as described below. For generation of
HCVcc virus stocks, cells were maintained in DMEMþ10% FBS;
supernatants were harvested every 2–3 days, when cells
were split, until % of infected cells declined (Gottwein et al.,
2007), as detected by immunostaining. High-titer stocks, collected
at the peak of viral infection, were used for further experiments.
Stocks with relatively low peak titers were concentrated using
Amicon 100 kDa centrifugation ﬁlters (Millipore). For generation
of sf-HCVcc virus stocks, DMEMþ10% FBS cell cultures
with 40–80% HCV infected cells were washed with PBS and
AEM was added. Cells were maintained in AEM, and supernatants
were harvested every 2–3 days, when AEM was exchanged,
for up to 29 days. Supernatants were sterile ﬁltered and stored
at 80 1C. The HCV Core-E2 sequences of all virus stocks used for
further experiments were determined by direct sequencing
(described below). Sequences were identical to the plasmid
sequence unless otherwise indicated in respective ﬁgure and table
legends.
Evaluation of HCV infected cell cultures
Spread of HCV recombinants in cell cultures was monitored by
HCV NS5A immunostaining. Cells plated onto chamber slides
(Nunc) the previous day were ﬁxed for 10 min in ice-cold acetone
(Sigma-Aldrich) and washed twice with PBS and twice with
PBSþ0.1% Tween-20 (Sigma-Aldrich). Cells were stained for HCV
NS5A using primary anti-NS5A antibody 9E10 (Lindenbach et al.,
2005) at 1:1000 dilution in PBSþ1% bovine serum albumin (BSA,
[Roche Applied Science])þ0.2% skim milk (PBS/BSK) for two hours
at room temperature. Cells were washed twice with PBS and twice
with PBSþ0.1% Tween-20 and stained using secondary antibody
Alexa Fluor 594-conjugated goat anti-mouse IgG (HþL) (Invitro-
gen) at 1:500 dilution and Hoechst 33342 (Invitrogen) at 1:1000
dilution in PBSþ0.1% Tween-20. Cells were washed twice in PBS,
before being covered by Fluoromount-G (SouthernBiotech) and a
cover-slip.
Culture supernatant infectivity titers were determined as
FFU/mL. Huh7.5 cells, plated at 6000 cells/well onto poly-D-lysine
coated 96-well plates (Nunc) the day before, were infected with
serially-diluted supernatants (lowest dilution 1:2). Forty-eight
hours after infection, cells were ﬁxed in ice-cold methanol and
washed twice with PBSþ0.1% Tween-20 before being incubated
with 3% H2O2 for ﬁve minutes at room temperature. Cells were
washed twice with PBSþ0.1% Tween-20 and HCV NS5A was
immunostained with primary anti-NS5A antibody 9E10 at
1:1000 dilution in PBS/BSK at 4 1C. The next day, cells were
washed twice with PBSþ0.1% Tween-20 and stained using sec-
ondary antibody ECL anti-mouse IgG horseradish peroxidase
(HRP)-linked whole antibody (GE Healthcare Amersham) at
1:300 in PBSþ0.1% Tween-20 for 30 min at room temperature
before being visualized by 30 min incubation at room temperature
with a DAB substrate kit (Dako). FFU were counted automatically
using an ImmunoSpot series 5 UV analyzer (CTL Europe GmbH)
with the customized software as described previously (Gottwein
et al., 2010). Lower limit of detection was calculated for each
96-well plate as the mean of at least 6 negative wells plus
3 standard deviations plus 3. Upper limit of detection was
set to 200 FFU/well as this was within the linear range of test
dilution series and comparable with manual determinations
(Scheel et al., 2011).
For determination of HCV RNA titers in culture supernatant,
RNA was extracted from 200 μL supernatant using the Total
Nucleic Acid Isolation Kit (Roche Applied Science); titers were
determined by TaqMan real-time PCR as previously described
(Gottwein et al., 2007). HCV Core titers in culture supernatant
were determined using the ARCHITECT HCV Ag assay (Abbott).
Direct sequencing of cell culture-derived HCV
HCV RNA was puriﬁed from 200 μL cell culture supernatant
using the High Pure Viral Nucleic Acid Kit (Roche Applied Science).
Overall, reverse transcription, 1st round PCR and 2nd round nested
PCR were carried out as previously described (Gottwein et al.,
2007). Primers used to generate cDNA and PCR amplicons span-
ning the Core-E2 region have been previously reported for H77(1a)
and ED43(4a) (Scheel et al., 2008); J4(1b) and HK6a(6a) (Gottwein
et al., 2009), J6(2a) and S52(3a) (Gottwein et al., 2007); as well as
SA13(5a) (Jensen et al., 2008). Direct sequencing of amplicons was
carried out by Macrogen Europe.
Single-cycle virus production assay in S29 cells
Overall, S29 cell experiments were carried out as previously
described (Serre et al., 2013). Brieﬂy, 400,000 CD81-deﬁcient S29
cells (Russell et al., 2008) were plated in 6-well plates 24 h before
transfection. In vitro HCV RNA transcripts of SA13(5a) (Jensen et
al., 2008) as well as of positive control (J6(2a)) and of negative
control (J6(2a)-GND) (Lindenbach et al., 2005) were generated
using T7 RNA polymerase (Promega) for 2 h at 37 1C, DNAse
treated using DNA RQ1 DNAse (Promega) and puriﬁed using
RNeasy kit (Qiagen). HCV RNA transcripts (2.5 mg) were mixed
with 5 mL Lipofectamine 2000 (Invitrogen) in 500 mL serum-free
Opti-MEM (Gibco/Invitrogen). S29 cells were incubated with
transfection complexes for 4 h in Opti-MEM. Following transfec-
tion, Opti-MEM was replaced by either DMEMþ10% FBS or AEM.
S29 cells were collected at 4, 24, 48 and 72 h post transfection and
prepared for determination of intracellular HCV Core and infectiv-
ity titers as previously described (Serre et al., 2013). Culture
supernatants were collected at 24, 48 and 72 h post transfection
for determination of extracellular HCV Core and infectivity titers.
Infectivity titers were determined as described above, while Core
titers were determined using the ARCHITECT HCV Ag assay
(Abbott).
Equilibrium density gradient ultracentrifugation
Semi-continuous 10–40% iodixanol gradients were prepared by
layering 2.5 mL of 40%, 30%, 20% and 10% OptiPrep (iodixanol;
Sigma-Aldrich) on top of each other as described previously
(Prentoe et al., 2011). HCVcc containing supernatants were either
loaded directly on top of the gradient, or concentrated using
Amicon 100 kDa centrifugation ﬁlters before loading. A ﬁnal
volume of 250 mL was loaded for all samples. The samples were
ultracentrifugated at 151,000 relative centrifugal force (RCF) for
18 h at 4 1C using a Beckman SW-41 rotor mounted in a Beckman
XL-70 ultracentrifuge. After centrifugation, fractions of 550 mL
were collected from the bottom of the tube and 400 mL portions
were weighed (model SI-114; Denver Instruments) to determine
fraction densities. Fraction infectivity titers were determined as
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described above. Iodixanol containing fractions were diluted to
contain r10% iodixanol before titration.
Receptor-, endocytosis- and neutralization assays
For receptor blocking assays we used Puriﬁed Mouse Anti-
Human CD81 primary antibody (JS-81) and Puriﬁed Mouse IgG1κ
isotype control (MOPC-21) (both BD Biosciences); Puriﬁed Goat
Anti-human LDLr polyclonal antibody (AF2148) and Normal Goat
IgG control (AB108C) (both R&D Systems); Anti-SR-BI primary
antibody (C16-71) and control antibody (D) were previously
described (Catanese et al., 2007). For HCVcc neutralization, we
used chronic-phase serum from patient H taken 29 years after
acute infection (H06 (Scheel et al., 2008)) and chronic-phase
serum from a genotype 5a infected patient (SA3 (Jensen et al.,
2008)) as well as a panel of monoclonal antibodies AR1B and
AR2A-5A, which were previously described (Giang et al., 2012;
Law et al., 2008). For ApoE neutralization we used a mouse
monoclonal primary antibody (1D7) blocking the ApoE receptor
binding site, and mouse IgG1κ (1D1) control antibody previously
described (Weisgraber et al., 1983). For inhibition of clathrin-
mediated endocytosis, we used chlorpromazine hydrochloride
(Calbiochem).
Huh7.5 cells were plated at 7000 cells/well onto poly-D-lysine
coated 96-well plates. On the following day, for receptor-blocking
assays, antibodies were diluted in DMEMþ10% FBS as speciﬁed
and added to cells for 1 h. For chlorpromazine assays, chlorpro-
mazine was diluted in DMEMþ10% FBS as speciﬁed and added to
cells for 30 min. HCVcc was diluted in DMEMþ10% FBS, whereas
sf-HCVcc was diluted in AEM with FBS concentration adjusted to
10%. Virus dilutions were added to the cells incubated with
blocking antibodies or chlorpromazine. Cell cultures were incu-
bated for an additional 6 h.
For HCV neutralization assays, chronic-phase HCV sera, or
AR1B and AR2A-5A monoclonal antibodies were diluted in
DMEMþ10% FBS as speciﬁed and mixed with either HCVcc or
sf-HCVcc diluted as for receptor blocking assays. Patient serum–
virus or antibody–virus mixes were incubated for 1 h, before
being added to cells. Cell cultures were incubated for 6 h. For
ApoE neutralization, 1D7 and 1D1 monoclonal antibodies were
diluted in DMEMþ10% FBS as speciﬁed and mixed with either
HCVcc or sf-HCVcc, diluted in DMEMþ10% FBS. Antibody–virus
mixes were incubated for 30 min, before being added onto cells.
Cell cultures were incubated for 3 h.
For blocking and neutralization assays, after 3 or 6 h incuba-
tion as indicated above, the cells were washed in PBS and
DMEMþ10% FBS was added to all cultures. Cells were incubated
and ﬁxed 48 h post infection in ice-cold methanol and HRP-
stained for HCV NS5A as described above. Single HCV NS5A
positive cells were counted automatically using an ImmunoSpot
series 5 UV analyzer (CTL Europe GmbH) with customized soft-
ware as described previously (Scheel et al., 2011; Gottwein et al.,
2011). The % blocking and neutralization were calculated by
relating counts of experimental wells to the mean count of six
replicate wells with untreated control virus. For receptor block-
ing and neutralization assays, following logarithmic transforma-
tion of X-values, variable-slope sigmoidal dose–response curves
[Y¼Bottomþ(Top–Bottom)/(1þ10(Log10EC50X)HillSlope)] were
ﬁtted to the data using GraphPad Prism 6.0. For receptor blocking
and neutralization assays “Bottom” was constrained to “0”. For
neutralization assays, “Top” was constrained to “100”, when
appropriate, as indicated in Figure legends, and median inhibi-
tory concentrations (IC50) were calculated using GraphPad
Prism 6.0. For receptor blocking assays, maximum blocking rates
(Bmax), the Y values at the top plateaus of the ﬁtted curves, were
calculated using GraphPad Prism 6.0.
HCV immunoprecipitation using anti-ApoE antibody
Immunoprecipitation was done using the ApoE-speciﬁc anti-
body 1D7 and isotype-matched control antibody 1D1 as pre-
viously described (Prentoe et al., 2014). Brieﬂy, 50 ml of
magnetic-bead slurry was washed in antibody binding buffer
(immunoprecipitation kit; Dynabeads Protein G; 100.070D; Invi-
trogen) and incubated on a shaker with 5 mg antibody in 50 ml
antibody binding buffer for 20 min at room temperature. The
beads were subsequently washed two times in washing buffer and
incubated with 106 IU of the virus in 200 ml of DMEM þ10% FBS on
a shaker for 1 h at room temperature. The beads were removed
and washed three times in 200 ml of washing buffer prior to
elution in 50 ml according to the manufacturer's instructions.
HCV RNA was extracted from the complete eluate and measured
in duplicates as previously described (Gottwein et al., 2007).
Cell viability and proliferation assays
For determination of Huh7.5 cell viability in DMEMþ10% FBS
versus AEM, we plated 6000 cells per well of poly-D-lysine coated
96-well plates in DMEMþ10% FBS. The following day, medium
was removed and cells were incubated in DMEMþ10% FBS or AEM
for 48 h. Then, cell viability was determined using the CellTiter
96s AQueous One Solution Cell Proliferation Assay kit (Promega)
according to the manufacturer's instructions. The % viability was
calculated by relating absorbance at 490 nm determined for 10
AEM cultures to the mean absorbance of 10 replicate DMEMþ10%
FBS cultures.
For determination of chlorpromazine cytotoxicity, chlorproma-
zine was diluted in DMEMþ10% FBS as speciﬁed and then added
to 6000 Huh7.5 cells/well, plated the previous day in poly-D-lysine
coated 96-well plates. Cells were incubated for 6 h before chlor-
promazine was removed and DMEMþ10% FBS was added. Cell
viability was determined 6 and 48 h post-treatment using the
CellTiter 96s AQueous One Solution Cell Proliferation Assay kit.
The % viability was calculated by relating absorbance at 490 nm
determined for chlorpromazine treated cultures to the mean
absorbance of at least three replicate untreated cultures.
For determination of Huh7.5 cell proliferation in DMEMþ10%
FBS versus AEM, we used the BrdU cell proliferation kit (Millipore).
Cells were plated in poly-D-lysine coated 96-well plates at 2000
cells/well in DMEMþ10% FBS according to the manufacturer's
instructions. The following day, medium was removed and cells
were incubated in DMEMþ10% FBS or AEM for 48 h. Then, cell
proliferation was determined using the BrdU cell proliferation kit
according to the manufacturer's instructions. The % proliferation
was calculated by relating absorbance at 450 nm determined for
10 replicate AEM cultures to the mean absorbance of 10 replicate
DMEMþ10% FBS cultures.
Flow cytometry
For surface staining of HCV co-receptors we used Phycoerythrin
(PE) Mouse Anti-Human CD81 primary antibody (BD Biosciences,
JS-81), Anti-mouse LDL R-Phycoerythrin primary antibody (R&D
systems, 263123), Puriﬁed Mouse Anti-Human CLA-1 (SR-BI)
primary antibody (BD Transduction Laboratories, 25/CLA-1) with
PE Goat Anti-Mouse Ig secondary antibody (BD Biosciences, poly-
clonal 550589) and Anti-human Claudin-1 primary antibody (R&D
systems, 421203) with PE Goat Anti-Rat Ig secondary antibody (BD
Biosciences, polyclonal 550767). Cells were detached by treatment
with a 10 mM solution of EDTA in PBS for 10 min at 37 1C. The cells
were washed in PBS and resuspended in FACS buffer (PBSþ1%
FBS) and 2.5105 cells/well were plated in a V-bottom 96-well
plate. Cells were stained protected from light at 4 1C for 1 h with
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either α-CD81 (25 μL/well according to the manufacturer's instruc-
tions), α-LDLr (10 μg/mL in FACS buffer), α-SR-BI (5 μg/mL in FACS
buffer) or α-Claudin-1 (5 μg/mL in FACS buffer). Total volume in all
wells was adjusted to 50 μL using FACS buffer. After incubation,
cells were washed in FACS buffer. SR-BI- and claudin-1-stained
cells were stained protected from light at 4 1C for 20 min with
secondary antibodies α-mouse Ig (4 μg/mL in FACS buffer) or α-rat
Ig (2 μg/mL in FACS buffer). Cells were washed in FACS buffer and
ﬁxed protected from light at room temperature for 15 min using
CellFix (BD Biosciences). Cells were washed and resuspended in
PBS before they were analyzed on a BD FACSCalibur ﬂow cyto-
meter using CellQuest Pro. Data analysis was done using FlowJo
ﬂow cytometry analysis software.
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